Radiopharmaceutical company Clarity Pharmaceuticals has announced site activation at the Children’s Hospital at Westmead in Sydney and recruitment has commenced for its SARTATE Kids trial.
Clarity’s trial is a Positron Emission Tomography (PET) imaging trial of paediatric patients with high-risk neuroblastoma using Copper-64 SARTATE.
It is a multi-centre, open-label, non-randomised Phase 1-2a imaging trial in 10 patients that is being led by Professor Robert Howman-Giles.
The Children’s Hospital at Westmead is one of the largest paediatric centres in New South Wales.
According to the company, additional sites in Australia and the US will be activated in the coming months with the goal of fast-tracking completion of this trial.
"The data from this trial will enable Clarity to progress Copper-67 SARTATE trials for the therapeutic treatment of neuroblastoma in children," it said.
Neuroblastoma is a disease that occurs most often in infants and young children, usually in children younger than 5 years old. It is the most common type of cancer to be diagnosed in the first year of life and accounts for around 13 per cent of paediatric cancer mortality. High-risk neuroblastoma accounts for approximately 45 per cent of all neuroblastoma cases. Patients with high-risk neuroblastoma have the lowest 5-year survival rates at 40-50 per cent.
“We are very excited to commence this trial at the Children's Hospital at Westmead and are looking forward to completing this important work," said Dr Alan Taylor, Clarity’s executive chairman. "Clarity is well positioned with its technology to pave the way for better therapies for children with cancer by trying to improve survival rates and significantly reduce long-term side effects. The ultimate goal is to ensure that these children not only survive, but live better lives post treatment."